Lauren K Stewart1, Daren M Beam2, Thomas Casciani2, Scott J Cameron3, Jeffrey A Kline4. 1. Department of Emergency Medicine, Indiana University School of Medicine, Indianapolis, IN, United States of America. 2. Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, United States of America. 3. Department of Cardiology, University of Rochester Medical Center, Rochester, NY, United States of America. 4. Department of Emergency Medicine, Department of Cellular and Integrative Physiology, Indiana University School of Medicine, 720 Eskenazi Ave, Indianapolis, IN 46202, United States of America. Electronic address: jefkline@iu.edu.
Abstract
BACKGROUND: Metabolic syndrome (MetS) has been associated with a procoagulant and hypofibrinolytic state. Current data exploring the role of MetS in venous thromboembolism (VTE) are limited. The objective was to measure the prevalence of MetS in patients with acute PE receiving catheter-directed thrombolysis (CDT) and to investigate its effect on mean pulmonary arterial pressure and overall treatment success. METHODS: We used a 3-year prospective registry of ED patients with acute PE with severity qualifying for activation of a PE response team (PERT). All patients had CDT with catheter-measured mPAP and angiography. The presence or absence of MetS components were extracted from chart review based on the following criteria: 1. body mass index (BMI) >30 kg/m2; 2. diagnosed hypertension; 3. diabetes mellitus (including HbA1c >6.5%) and; 4. dyslipidemia (including triglycerides >150 mg/dL or high-density lipoprotein <40 mg/dL). RESULTS: Of the 134 patients, 85% met the criteria for at least one of four MetS components, with obesity being most common, present in 71%. Results demonstrated a positive concordance between the number of criteria for MetS and MPAP, both pre- and post-fibrinolysis, as pressures tended to increase with each additional MetS criterion. Multivariate regression analysis determined age (-), BMI (+) and hypertension (+) to be significant independent predictor variables for mPAP. CONCLUSIONS: MetS was common in patients with more severe manifestations of PE and was associated with higher mPAP values both at diagnosis and following treatment with CDT.
BACKGROUND:Metabolic syndrome (MetS) has been associated with a procoagulant and hypofibrinolytic state. Current data exploring the role of MetS in venous thromboembolism (VTE) are limited. The objective was to measure the prevalence of MetS in patients with acute PE receiving catheter-directed thrombolysis (CDT) and to investigate its effect on mean pulmonary arterial pressure and overall treatment success. METHODS: We used a 3-year prospective registry of ED patients with acute PE with severity qualifying for activation of a PE response team (PERT). All patients had CDT with catheter-measured mPAP and angiography. The presence or absence of MetS components were extracted from chart review based on the following criteria: 1. body mass index (BMI) >30 kg/m2; 2. diagnosed hypertension; 3. diabetes mellitus (including HbA1c >6.5%) and; 4. dyslipidemia (including triglycerides >150 mg/dL or high-density lipoprotein <40 mg/dL). RESULTS: Of the 134 patients, 85% met the criteria for at least one of four MetS components, with obesity being most common, present in 71%. Results demonstrated a positive concordance between the number of criteria for MetS and MPAP, both pre- and post-fibrinolysis, as pressures tended to increase with each additional MetS criterion. Multivariate regression analysis determined age (-), BMI (+) and hypertension (+) to be significant independent predictor variables for mPAP. CONCLUSIONS: MetS was common in patients with more severe manifestations of PE and was associated with higher mPAP values both at diagnosis and following treatment with CDT.
Authors: Lauren K Stewart; Geoffrey W Peitz; Kristen E Nordenholz; D Mark Courtney; Christopher Kabrhel; Alan E Jones; Matthew T Rondina; Deborah B Diercks; James R Klinger; Jeffrey A Kline Journal: J Thromb Thrombolysis Date: 2015-08 Impact factor: 2.300
Authors: John A Watts; Michael A Gellar; Lori K Stuart; Maria Obraztsova; Jeffrey A Kline Journal: J Cardiovasc Pharmacol Date: 2009-09 Impact factor: 3.105
Authors: K G M M Alberti; Robert H Eckel; Scott M Grundy; Paul Z Zimmet; James I Cleeman; Karen A Donato; Jean-Charles Fruchart; W Philip T James; Catherine M Loria; Sidney C Smith Journal: Circulation Date: 2009-10-05 Impact factor: 29.690
Authors: Mary Cushman; Albert W Tsai; Richard H White; Susan R Heckbert; Wayne D Rosamond; Paul Enright; Aaron R Folsom Journal: Am J Med Date: 2004-07-01 Impact factor: 4.965
Authors: Mostafa Wanees Ahmed El Husseny; Mediana Mamdouh; Sara Shaban; Abdelrahman Ibrahim Abushouk; Marwa Mostafa Mohamed Zaki; Osama M Ahmed; Mohamed M Abdel-Daim Journal: J Diabetes Res Date: 2017-02-13 Impact factor: 4.011